Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study

Hiroki Ishihara(Tokyo Women's Medical University), Kazunari Tanabe(Shonan Kamakura General Hospital), Hidekazu Tachibana, Hirohito Kobayashi(Ebina General Hospital), Kazuhiko Yoshida(Tokyo Women's Medical University Hospital), Hironori Fukuda(Tokyo Women's Medical University), Takashi Ikeda(Tokyo Women's Medical University), Yasunobu Hashimoto, Yuki Nemoto(Tokyo Women's Medical University Adachi Medical Center), Tsunenori Kondo(Tokyo Women's Medical University Adachi Medical Center), Hiroaki Shimmura(Jyoban Hospital of Tokiwa Foundation), Junpei Iizuka(Tokyo Women's Medical University), Toshio Takagi(Tokyo Women's Medical University), Hideki Ishida(Tokyo Women's Medical University), Kazutaka Nakamura(Tokyo Women's Medical University Hospital)
Targeted Oncology
June 26, 2021
Cited by 9


Related Papers